Oxford PharmaScience is a pharmaceutical technology company licensing innovative reformulation technologies for prescription and OTC drugs. We are experts in the application of layered double hydroxides to drug and biomolecule delivery.
Oxford PharmaScience was founded following research collaborations with the University of Oxford, and has since built a broad IP portfolio through in-house development and in-licensing from university partners, underpinning the OXPzero™ platform.
Our Approach
• Engineered control of onset and systemic exposure
• Clear regulatory pathways leveraging established API safety profiles
• Improved consumer experience through intrinsic taste masking and format flexibility
• Applicable across a broad range of anionic APIs and biomolecules, and multiple dosage forms
We operate an asset-light model, focusing on platform development while working in partnership with pharmaceutical companies around the world to develop specific applications of the technology.
Current Focus
Our platform technology offers multiple market applications, streamlined development timelines, flexible formulation options, and strong IP protection. We work with partners to license specific applications of the platform for development and commercialisation — for example, a fast-acting ibuprofen formulation (Oxprofen™), demonstrating the platform's ability to modulate drug release and absorption in a mature therapeutic category.
Partnership
For partnership inquiries: contact@pharmascience.co.uk